Prediabetes now affects hundreds of millions of people worldwide, yet for many, it represents a critical window of opportunity—where early nutritional and lifestyle interventions can meaningfully improve metabolic health.
A recently published clinical trial in Bioactive Compounds in Health and Disease adds to the growing body of evidence that dietary bioactives can play a powerful role in glucose regulation.
What Was Studied?
Researchers evaluated a proprietary dietary supplement Brightseed® BioMetaControl, containing bioactives N-trans caffeoyltyramine (NCT) and N-trans feruloyltyramine (NFT)—two naturally occurring plant compounds previously identified as agonists of HNF4α, a key metabolic regulator sometimes referred to as a “master switch” for glucose metabolism.
In a randomized, double-blind, placebo-controlled trial, 126 adults with prediabetes took either 120 mg/day of BioMetaControl or a placebo for four weeks. Importantly, the study combined traditional fasting blood markers with continuous glucose monitoring (CGM), allowing researchers to assess real-world glucose patterns throughout the day.
Key Findings
Participants receiving NCT/NFT experienced:
- Significant reductions in fasting blood glucose
- Improved fasting insulin levels
- Lower postprandial (after-meal) glucose responses
- Significantly less time spent outside the ideal glucose range, as measured by CGM
These improvements were observed without changes in body weight, lipid levels, or diet—and with no supplement-related adverse events reported.
Why This Matters
Most nutrition studies rely on single “snapshot” measurements like fasting glucose. This trial went further, using CGM to show how BioMetaControl with NCT/NFT helped smooth glucose excursions across the day. That matters because frequent glucose spikes and prolonged time above healthy ranges are increasingly recognized as drivers of long-term metabolic dysfunction.
The findings suggest that targeting HNF4α through food-derived bioactives may complement existing lifestyle strategies—and potentially support individuals seeking non-pharmacological options to maintain healthy blood glucose levels.
Looking Ahead
While longer-term studies are needed, this research represents an important step in translating bioactive discovery into clinically validated nutrition solutions. It also highlights the promise of AI to identify and help bring to market impactful, non-obvious multi-ingredient formulations.
The bioactives used in this study are now available in BioMetaControl, a commercially-available GLP-1 companion that’s low-dose and easy to formulate across a variety of formats.You can read the full peer-reviewed study here: Bioactive Compounds in Health and Disease (2025).
